In 2023, Paul Lonergan embarked on an extensive search to uncover the cause of his persistent sore throat. Following numerous consultations with medical professionals, the Toronto resident was given a startling revelation: he had a sizable tumor located at the base of his tongue.
Realizing the challenge ahead, the 68-year-old underwent a grueling seven-week regimen of radiation and chemotherapy, enduring intensive care unit visits to eradicate all traces of his tumor. However, the question remained: had his cancer truly been eradicated?
Participating in a clinical trial facilitated by his healthcare team, Lonergan underwent a “liquid biopsy” to determine the status of his cancer. This innovative cancer detection method employs simple blood tests to detect tumor DNA not visible in conventional scans and examinations. Results revealed residual tumor fragments in Lonergan’s blood, indicating a potential resurgence of his successfully treated tongue cancer.
Subsequently offered experimental immunotherapy, Lonergan has remained cancer-free, as confirmed by subsequent rounds of liquid biopsies monitoring his blood for any minute traces of the disease.
While access to this cutting-edge cancer monitoring technique remains limited in Canada, predominantly within clinical trial settings or costly private facilities, there is a growing optimism for broader accessibility. Dr. Ramy Saleh, a cancer researcher and medical oncologist at McGill University Health Centre, believes this approach has the capacity to revolutionize disease recurrence surveillance.
A Toronto-based team has initiated an extensive research endeavor spanning several years to explore the integration of this emerging technology into routine patient care. The primary objective is to develop improved strategies to safeguard cancer survivors from potential relapse, while sparing them from costly, invasive treatments.
Named SHERLOCK, the project led by scientists from the University Health Network in Toronto aims to offer liquid biopsies to over 7,000 patients who have undergone traditional curative cancer treatments, over a five-year period. Dr. Lillian Siu, the study lead, underscores the goal of detecting circulating tumor DNA signaling a possible cancer recurrence.
As the research delves into uncovering hidden disease indicators, Siu’s team endeavors to detect cancer at earlier stages through blood tests before conventional clinical or imaging methods can identify it. The ultimate goal is to intervene sooner and enhance the chances of providing patients with curative interventions.
Continued monitoring through liquid biopsies may lead to referrals for next-generation treatments in instances of early warning signs. This could involve experimental immunotherapy, novel drugs, or specialized medications like GLP-1s to potentially eliminate cancer entirely.
Moreover, the project aims to explore scenarios where patients may abstain from extensive treatments if no residual disease is detected in their blood, emphasizing a personalized approach to healthcare.
Liquid biopsy technology, although relatively new, has shown promising potential in detecting residual disease post-surgery and prolonging survival rates for various cancer types. Ongoing research is crucial to establish the utility of liquid biopsies in different cancer scenarios and guide appropriate follow-up care strategies.
The aspiration is to integrate liquid biopsies into routine clinical practice, despite associated costs. The increasing number of global clinical trials signifies growing enthusiasm for this technology and its potential to enhance patient outcomes while optimizing healthcare expenditures.